Thus, the pharmaceutical targeting on YAP/Notch/HIF signaling pathways has been proposed as a potential adjunct therapy for cancer treatment, along with the conventional chemotherapy and immune therapy (Janghorban et al., 2018). The gene discussed is YAP1; the disease is cancer.